Abstract
Background Transcranial direct current stimulation (tDCS) has been proposed as a novel treatment in major depressive disorder (MDD). However, efficacy and safety of home-based tDCS treatment have not been investigated.
Methods Fully remote, multisite, double-blind, placebo-controlled, randomized superiority trial of home-based tDCS treatment in MDD was conducted in UK and USA. Participants were adults 18 years or older, having MDD diagnosis based on DSM-5 criteria, in current depressive episode of at least moderate severity, measured by score >=16 on 17-item Hamilton Depression Rating Scale (HDRS), without treatment resistant depression history. Protocol was 10-week blinded phase: 5 tDCS sessions per week for 3 weeks then 3 sessions per week for 7 weeks; followed by 10-week open label phase. tDCS montage was bifrontal, 30-minute sessions, active tDCS 2 mA, and sham tDCS 0 mA with brief ramp up and down to mimic active device. Primary outcome was HDRS change at week 10 in modified intention-to-treat analysis.
Results 174 MDD participants were randomized: active (n=87; mean age 37.1 ± 11.1 years) and sham (n=87; mean age 38.3 ± 10.9 years) treatment. Significant improvement in HDRS was observed in active (9.4 ± 6.25 points) relative to sham treatment (7.1 ± 6.10 points) (95% CI 0.5 to 4.0, p = 0.012), with no differences in discontinuation rates between active (n=13) and sham (n=12).
Conclusions Home-based tDCS with remote supervision is a potential first line treatment for MDD that is acceptable and safe. Consideration of continuing effective safety monitoring is required.
Trial registration number NCT05202119
Competing Interest Statement
AHY reports declaration of interests: Employed by Kings College London; Honorary Consultant South London and Maudsley NHS Foundation Trust (NHS UK). Editor of Journal of Psychopharmacology and Deputy Editor, BJPsych Open. Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Flow Neuroscience, Novartis, Roche, Janssen, Takeda, Noema pharma, Compass, Astrazenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, Sage, Novartis, Neurocentrx. Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK) EU Horizon 2020. Principal Investigator on the following trials;1. the Restore-Life VNS registry study funded by LivaNova; 2. ESKETINTRD3004: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression; 3. The Effects of Psilocybin on Cognitive Function in Healthy Participants; 4. The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD); 5. A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy. (Janssen); 6. An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants with Major Depressive Disorder (MDD). (Janssen); 7. A Randomized, Double-blind, Multicentre, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy; 8. A Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients with Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNR. (Janssen). UK Chief Investigator for Compass; COMP006 & COMP007 studies. UK Chief Investigator for Novartis MDD study MIJ821A12201. No shareholdings in pharmaceutical companies SS received research grant funding from Flow Neuroscience to the University of Texas Health Science Center at Houston for the present manuscript. Additional disclosures are within the past 36 months. Research grant funding payments made to the University of Texas Health Science Center at Houston include: NIMH (1R21MH119441-01A1; 1R21MH129888-01A1), NICHD (1R21HD106779-01A1), SAMHSA (6H79FG000470-01M003). Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for Psychiatry education forum and NIH study section reviewer. Participation on a Data Safety Monitoring Board or Advisory Board for Worldwide Clinical Trials and Inversago and Vicore pharma. Stock or Stock options in Intra-Cellular Therapies as a full time employee and Biogen. Participated in clinical trials as site sub-investigator - University of Texas Health Science Center at Houston for the following: COMPASS Pathways, LivaNova, Janssen and Relmada. Consulting fees from Boxer Capital. Royalties or licenses from Cambridge University Press (no payments have been received). CHYF received research grant funding from Flow Neuroscience to the University of East London for the present manuscript. Additional disclosures are within the past 36 months. Research grant funding payments made to institutions include: Baszucki Brain Research Milken Institute (0000000029), Institute of Psychoanalysis (IPA0158), NIMH (RO1MH134236), Rosetrees Trust (CF20212104). JCS disclosures from the past 36 months include grants or contracts from Milken, Compass Pathways and MindMed. Consulting fees from Livanova, Boehringer Ingleheim, Johnson & Johnson, and Sunovian. Participation on a Data Safety Monitoring Board or Advisory Board for Alkermes. DM works for Biomedical Statistical Consulting. Biomedical Statistical Consulting provides statistical support to MCRA, LLC who received payments from Flow Neuroscience. LH works for Biomedical Statistical Consulting. Biomedical Statistical Consulting provides statistical support to MCRA, LLC who received payments from Flow Neuroscience. PL was paid to work on the trial for a period of approximately 3 months as an Assistant Researcher at a level commensurate with that role. Authors GS, AN, RW, NL, HH, MR, PO, RMV and SK declare that they have no competing interests to declare.
Clinical Trial
NCT05202119
Funding Statement
The study was funded by Flow Neuroscience.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In UK, South Central-Hampshire B Research Ethics Committee gave ethical approval for this work. In Texas, USA, WIRB-Copernicus Group International Review Board gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revision 1: Figure S2 in the supplementary appendix 'Change in Montgomery-Asberg Depression Rating Scale (MADRS) ratings over time' had an incorrect label on the y axis. This has been updated from 'MADRS-s score' to the correct label 'MADRS score'. Revision 2: Figure S9 in the supplementary appendix 'Percentage of participants in active and sham groups who endorsed each response in the acceptability questionnaire at baseline and week 10' had the incorrect labels for the 'Burden' bar chart. 'More effort than usual' and 'Less effort than usual' had been positioned on the wrong sides of the x axis. This has been updated and the 'Burden' bar chart now correctly reflects the responses.
Data Availability
None of the data in the present manuscript will be made available.
